Literature DB >> 2469014

Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells.

C Saltini1, K Winestock, M Kirby, P Pinkston, R G Crystal.   

Abstract

Chronic beryllium disease is characterized by the accumulation of helper/inducer T cells, macrophages, and granulomas in the lungs. To evaluate the hypothesis that the proliferation of CD4+ (helper/inducer) T cells in the lungs of patients with this disorder is maintained by local activation of beryllium-specific T-cell clones, we studied T cells obtained from peripheral blood and by bronchoalveolar lavage in eight patients and five healthy controls. The proliferation of T cells in response to beryllium in vitro was confined to the CD4+ T cells from the patients and was dependent on the presentation of antigen in the presence of both major histocompatibility complex class II antigens and functional interleukin-2 receptors. T cells from the patients' lungs had a significantly greater response to beryllium than did T cells from their peripheral blood (stimulation index, 103 vs. 5; P less than 0.01). Lines and clones of cells developed from T cells from the patients' lungs showed dose-dependent proliferation in response to beryllium but did not respond to recall antigens or to other metals. Although all beryllium-specific T-cell clones were CD4+ and none were CD8+ (suppressor/cytotoxic), all beryllium-specific clones studied had different rearrangements of T-cell antigen receptors, suggesting that the response to beryllium involved T cells with diverse specificities for beryllium. We conclude that in patients with chronic beryllium disease, beryllium acts as a class II-restricted antigen, stimulating local proliferation and accumulation in the lung of beryllium-specific CD4+ (helper/inducer) T cells. Hence, chronic beryllium disease is a hypersensitivity disease in which beryllium is the specific antigen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469014     DOI: 10.1056/NEJM198904273201702

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  44 in total

Review 1.  Clinical application of beryllium lymphocyte proliferation testing.

Authors:  Barbara P Barna; Daniel A Culver; Belinda Yen-Lieberman; Raed A Dweik; Mary Jane Thomassen
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

3.  Increased numbers of T lymphocytes with gamma delta-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis.

Authors:  B Balbi; D R Moller; M Kirby; K J Holroyd; R G Crystal
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

4.  The bioinorganic chemistry and associated immunology of chronic beryllium disease.

Authors:  Brian L Scott; T Mark McCleskey; Anu Chaudhary; Elizabeth Hong-Geller; S Gnanakaran
Journal:  Chem Commun (Camb)       Date:  2008-05-09       Impact factor: 6.222

5.  Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects.

Authors:  Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2010-03-18       Impact factor: 21.405

6.  Scintigraphy with J001X, a Klebsiella membrane glycolipid, for the early diagnosis of chronic berylliosis: results from an experimental model.

Authors:  P Diot; A Le Pape; D Nolibe; G Normier; H Binz; J P Revillard; G Lasfargues; M Lavandier; E Lemarié
Journal:  Br J Ind Med       Date:  1992-05

Review 7.  Respiratory diseases.

Authors:  D G James; O M Sharma
Journal:  Postgrad Med J       Date:  1990-01       Impact factor: 2.401

8.  Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway.

Authors:  Brian C Tooker; Stephen M Brindley; Marina L Chiarappa-Zucca; Kenneth W Turteltaub; Lee S Newman
Journal:  J Immunotoxicol       Date:  2014-06-16       Impact factor: 3.000

9.  CC chemokine receptor 5 gene polymorphisms in beryllium disease.

Authors:  H Sato; L Silveira; P Spagnolo; M Gillespie; E B Gottschall; K I Welsh; R M du Bois; L S Newman; L A Maier
Journal:  Eur Respir J       Date:  2010-01-14       Impact factor: 16.671

10.  4-1BB enhances proliferation of beryllium-specific T cells in the lung of subjects with chronic beryllium disease.

Authors:  Douglas G Mack; Allison K Lanham; Brent E Palmer; Lisa A Maier; Tania H Watts; Andrew P Fontenot
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.